DelSiTech Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
DelSiTech Ltd. - overview
Established
2001
Location
Turku, -, Finland
Primary Industry
Biotechnology
About
Based in Turku, Finland, and founded in 2001 and led by CEO Lasse Leino, DelSiTech Ltd. operates as a biotechnology company that provides pharmaceutical development and medical technology services. In January 2024, DelSiTech Ltd. raised EUR 10 million in venture funding co-led by DRW Venture Capital and Tolmar International Ltd.
DelSiTech Ltd. developed a product known as DelSiTech Silica, which is an advanced delivery technology designed for parenteral and local administration in injectable depots, implants, and eye drop dosage forms. The technology involves embedding active ingredients within a silica matrix, which can be engineered to biodegrade at a specific rate. This ensures a controlled release of the active substance over extended periods, enhancing the therapeutic effect and patient compliance.
The company’s product pipeline includes supergeneric/505(b)(2) products, targeting unmet medical needs with first-in-class and differentiated offerings.
Current Investors
Bill & Melinda Gates Foundation, DRW Venture Capital, DRW Venture Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.delsitech.com/
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.